P159 Innate-like CD56 <sup>+</sup> CD8 <sup>+</sup> T cells exhibit bystander function and metabolic sensitivity in chronic hepatitis B

<h3></h3> CD56<sup>+</sup> CD8<sup>+</sup> T cells straddle innate and adaptive immunity, distinguished by natural killer receptor (NKR) expression and the capacity for TCR-independent, bystander effector functions. These cells are implicated in liver inflammation and may represent a barrier to immune restoration in chronic hepatitis B (CHB). Given emerging evidence that metabolic dysfunction-associated steatotic liver disease (MASLD) co-existing with CHB (CHB-MASLD) is associated with delayed viral responses and persistent inflammation, understanding the behaviour of CD56<sup>+</sup> CD8<sup>+</sup> T cells may provide insights into immunometabolic dysregulation relevant to both CHB and CHB-MASLD. We investigated circulating CD8<sup>+</sup> T cells in healthy controls (HC) and CHB patients (treatment-naïve and on antiviral therapy, AVT). Multi-parameter flow cytometry was used to assess activation status, NKR expression, response to free fatty acids (FFAs), and effector function. CD8<sup>+</sup> T cells were also sorted for transcriptomic analysis. Activated (CD38<sup>+</sup>HLA-DR<sup>+</sup>) CD8<sup>+</sup> T cells expressing CD56 were significantly expanded in CHB patients compared to HCs, with increased expression of NKRs (NKG2A, NKp30). These innate-like CD56<sup>+</sup> CD8<sup>+</sup> T cells were more prevalent in ‘immune active’ than ‘immune control’ disease. AVT-treated patients had reduced proportions of CD56<sup>+</sup> CD8<sup>+</sup> T cells, yet their NKR expression remained high, indicating persistent innate-like signatures. Transcriptomic profiling revealed upregulation of innate-associated genes (e.g., KLRK1, NCR3) in AVT-treated patients compared to untreated controls. Functionally, CD56<sup>+</sup> CD8<sup>+</sup> T cells showed comparable IFN-γ production following TCR-dependent (anti-CD3/CD28) and TCR-independent (IL-15) stimulation, but TNF-α production was significantly higher following IL-15 stimulation, confirming a differential functional and bystander activation profile. These cells were also more susceptible to suppression by FFAs, suggesting functional vulnerability in metabolically altered environments. Our findings show that CD56<sup>+</sup> CD8<sup>+</sup> T cells with innate-like features are expanded and functionally distinct in CHB, with persistent NKR expression despite AVT and heightened sensitivity to metabolic cues. The susceptibility of these cells to FFAs supports a potential mechanistic link between metabolic dysfunction and immune dysregulation in CHB-MASLD. The exploration of the immunometabolic contribution of CD56<sup>+</sup> CD8<sup>+</sup> T cells to therapeutic resistance and liver disease progression appears critical in CHB and CHB-MASLD .

Authors

Institutions

Publication Details

Published
2025-10-01
DOI
https://doi.org/10.1136/gutjnl-2025-basl.169
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P159 Innate-like CD56 + CD8 + T cells exhibit bystander function and metabolic sensitivity in chronic hepatitis B

Apostolos Koffas, Tizong Miao, Katrin Böttcher, Carina Mascarenhas Fernandes et al.
Hepatitis B Virus Studies
article

P159 Innate-like CD56 + CD8 + T cells exhibit bystander function and metabolic sensitivity in chronic hepatitis B

Apostolos Koffas, Tizong Miao, Katrin Böttcher, Carina Mascarenhas Fernandes, Patrick T.F. Kennedy, Gerard Hernández-Mir, Lung‐Yi Mak, Upkar S. Gill, Sebastian Deschler, Corinna Pade, Lei Yu, Shue Xiong, Anna Riddell
article en

Abstract

<h3></h3> CD56<sup>+</sup> CD8<sup>+</sup> T cells straddle innate and adaptive immunity, distinguished by natural killer receptor (NKR) expression and the capacity for TCR-independent, bystander effector functions. These cells are implicated in liver inflammation and may represent a barrier to immune restoration in chronic hepatitis B (CHB). Given emerging evidence that metabolic dysfunction-associated steatotic liver disease (MASLD) co-existing with CHB (CHB-MASLD) is associated with delayed viral responses and persistent inflammation, understanding the behaviour of CD56<sup>+</sup> CD8<sup>+</sup> T cells may provide insights into immunometabolic dysregulation relevant to both CHB and CHB-MASLD. We investigated circulating CD8<sup>+</sup> T cells in healthy controls (HC) and CHB patients (treatment-naïve and on antiviral therapy, AVT). Multi-parameter flow cytometry was used to assess activation status, NKR expression, response to free fatty acids (FFAs), and effector function. CD8<sup>+</sup> T cells were also sorted for transcriptomic analysis. Activated (CD38<sup>+</sup>HLA-DR<sup>+</sup>) CD8<sup>+</sup> T cells expressing CD56 were significantly expanded in CHB patients compared to HCs, with increased expression of NKRs (NKG2A, NKp30). These innate-like CD56<sup>+</sup> CD8<sup>+</sup> T cells were more prevalent in ‘immune active’ than ‘immune control’ disease. AVT-treated patients had reduced proportions of CD56<sup>+</sup> CD8<sup>+</sup> T cells, yet their NKR expression remained high, indicating persistent innate-like signatures. Transcriptomic profiling revealed upregulation of innate-associated genes (e.g., KLRK1, NCR3) in AVT-treated patients compared to untreated controls. Functionally, CD56<sup>+</sup> CD8<sup>+</sup> T cells showed comparable IFN-γ production following TCR-dependent (anti-CD3/CD28) and TCR-independent (IL-15) stimulation, but TNF-α production was significantly higher following IL-15 stimulation, confirming a differential functional and bystander activation profile. These cells were also more susceptible to suppression by FFAs, suggesting functional vulnerability in metabolically altered environments. Our findings show that CD56<sup>+</sup> CD8<sup>+</sup> T cells with innate-like features are expanded and functionally distinct in CHB, with persistent NKR expression despite AVT and heightened sensitivity to metabolic cues. The susceptibility of these cells to FFAs supports a potential mechanistic link between metabolic dysfunction and immune dysregulation in CHB-MASLD. The exploration of the immunometabolic contribution of CD56<sup>+</sup> CD8<sup>+</sup> T cells to therapeutic resistance and liver disease progression appears critical in CHB and CHB-MASLD .

Queen Mary University of London (GB), Barts Health NHS Trust (GB), University Children's Hospital Tübingen (DE), University of Hong Kong (HK)
Openalex Percentile: Top 62%
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.